BioNTech Investor Presentation Deck

Oncology Programs in Phase 2 Platform Fix Vac Program BNT111 How Why Off-the-shelf mRNA vaccine 24 R/R Melanoma Encodes 4 tumor- associated antigens U.S. Fast Track Designation and Orphan Drug Designation Potential to improve outcomes in combo with anti-PD1 BNT113 HPV16+ HNSCC Encodes HPV16 oncoproteins Potential for synergistic anti-tumor effect in combination with anti-PD1 iNeST Individualized mRNA immunotherapy BNT122 Autogene cevumeran¹ 1L Melanoma Targets 20 neo-antigens unique to each patient Data update expected 1H 2023 Trial success may unlock 1L use of iNeST as combination therapy with anti-PD (L)1 in anti-PD1- naive advanced cancers BNT122 Autogene cevumeran¹ Adjuvant colorectal cancer Targets 20 neo-antigens unique to each patient Potential to address residual cancer cells that remain focus on recurrence free survival R/R, refractory/relapsed; HPV16+, human papilloma virus type 16 positive; HNSCC, head and neck squamous cell carcinoma; NK cell, natural killer cell; CPI, checkpoint inhibitor 1 Collaboration with Genentech, 2 Collaboration with Genmab. Bispecific Next-generation immunotherapy BNT311² R/R NSCLC Conditional 4-1BB co- stimulation while blocking PD(L)1 axis Enhances T-cell and NK cell function and targets them to tumor lesions BIONTECH

View entire presentation